120 related articles for article (PubMed ID: 38244557)
1. Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial.
Kaasch AJ; López-Cortés LE; Rodríguez-Baño J; Cisneros JM; Dolores Navarro M; Fätkenheuer G; Jung N; Rieg S; Lepeule R; Coutte L; Bernard L; Lemaignen A; Kösters K; MacKenzie CR; Soriano A; Hagel S; Fantin B; Lafaurie M; Talarmin JP; Dinh A; Guimard T; Boutoille D; Welte T; Reuter S; Kluytmans J; Martin ML; Forestier E; Stocker H; Vitrat V; Tattevin P; Rommerskirchen A; Noret M; Adams A; Kern WV; Hellmich M; Seifert H;
Lancet Infect Dis; 2024 May; 24(5):523-534. PubMed ID: 38244557
[TBL] [Abstract][Full Text] [Related]
2. Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO): study protocol for a randomized controlled trial.
Kaasch AJ; Fätkenheuer G; Prinz-Langenohl R; Paulus U; Hellmich M; Weiß V; Jung N; Rieg S; Kern WV; Seifert H;
Trials; 2015 Oct; 16():450. PubMed ID: 26452342
[TBL] [Abstract][Full Text] [Related]
3. Protocol update for the SABATO trial: a randomized controlled trial to assess early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection.
Kaasch AJ; Rommerskirchen A; Hellmich M; Fätkenheuer G; Prinz-Langenohl R; Rieg S; Kern WV; Seifert H;
Trials; 2020 Feb; 21(1):175. PubMed ID: 32051007
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.
François B; Jafri HS; Chastre J; Sánchez-García M; Eggimann P; Dequin PF; Huberlant V; Viña Soria L; Boulain T; Bretonnière C; Pugin J; Trenado J; Hernandez Padilla AC; Ali O; Shoemaker K; Ren P; Coenjaerts FE; Ruzin A; Barraud O; Timbermont L; Lammens C; Pierre V; Wu Y; Vignaud J; Colbert S; Bellamy T; Esser MT; Dubovsky F; Bonten MJ; Goossens H; Laterre PF;
Lancet Infect Dis; 2021 Sep; 21(9):1313-1323. PubMed ID: 33894131
[TBL] [Abstract][Full Text] [Related]
5. Oral versus intravenous antibiotics for bone and joint infections: the OVIVA non-inferiority RCT.
Scarborough M; Li HK; Rombach I; Zambellas R; Walker AS; McNally M; Atkins B; Kümin M; Lipsky BA; Hughes H; Bose D; Warren S; Mack D; Folb J; Moore E; Jenkins N; Hopkins S; Seaton RA; Hemsley C; Sandoe J; Aggarwal I; Ellis S; Sutherland R; Geue C; McMeekin N; Scarborough C; Paul J; Cooke G; Bostock J; Khatamzas E; Wong N; Brent A; Lomas J; Matthews P; Wangrangsimakul T; Gundle R; Rogers M; Taylor A; Thwaites GE; Bejon P
Health Technol Assess; 2019 Aug; 23(38):1-92. PubMed ID: 31373271
[TBL] [Abstract][Full Text] [Related]
6. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.
Dinh A; Ropers J; Duran C; Davido B; Deconinck L; Matt M; Senard O; Lagrange A; Makhloufi S; Mellon G; de Lastours V; Bouchand F; Mathieu E; Kahn JE; Rouveix E; Grenet J; Dumoulin J; Chinet T; Pépin M; Delcey V; Diamantis S; Benhamou D; Vitrat V; Dombret MC; Renaud B; Perronne C; Claessens YE; Labarère J; Bedos JP; Aegerter P; Crémieux AC;
Lancet; 2021 Mar; 397(10280):1195-1203. PubMed ID: 33773631
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial.
Ibrahim LF; Hopper SM; Orsini F; Daley AJ; Babl FE; Bryant PA
Lancet Infect Dis; 2019 May; 19(5):477-486. PubMed ID: 30853250
[TBL] [Abstract][Full Text] [Related]
9. Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT.
Coyle V; Forde C; Adams R; Agus A; Barnes R; Chau I; Clarke M; Doran A; Grayson M; McAuley D; McDowell C; Phair G; Plummer R; Storey D; Thomas A; Wilson R; McMullan R
Health Technol Assess; 2024 Mar; 28(14):1-101. PubMed ID: 38512064
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of switching from intravenous to oral antibiotics (amoxicillin-clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiority trial.
Keij FM; Kornelisse RF; Hartwig NG; van der Sluijs-Bens J; van Beek RHT; van Driel A; van Rooij LGM; van Dalen-Vink I; Driessen GJA; Kenter S; von Lindern JS; Eijkemans M; Stam-Stigter GM; Qi H; van den Berg MM; Baartmans MGA; van der Meer-Kappelle LH; Meijssen CB; Norbruis OF; Heidema J; van Rossem MC; den Butter PCP; Allegaert K; Reiss IKM; Tramper-Stranders GA
Lancet Child Adolesc Health; 2022 Nov; 6(11):799-809. PubMed ID: 36088952
[TBL] [Abstract][Full Text] [Related]
11. Individualised, short-course antibiotic treatment versus usual long-course treatment for ventilator-associated pneumonia (REGARD-VAP): a multicentre, individually randomised, open-label, non-inferiority trial.
Mo Y; Booraphun S; Li AY; Domthong P; Kayastha G; Lau YH; Chetchotisakd P; Limmathurotsakul D; Tambyah PA; Cooper BS;
Lancet Respir Med; 2024 May; 12(5):399-408. PubMed ID: 38272050
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated Staphylococcus aureus bacteremia (SAB7): study protocol for a randomized controlled trial.
Thorlacius-Ussing L; Andersen CØ; Frimodt-Møller N; Knudsen IJD; Lundgren J; Benfield TL
Trials; 2019 May; 20(1):250. PubMed ID: 31046810
[TBL] [Abstract][Full Text] [Related]
13. Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial.
Patil V; Noronha V; Dhumal SB; Joshi A; Menon N; Bhattacharjee A; Kulkarni S; Ankathi SK; Mahajan A; Sable N; Nawale K; Bhelekar A; Mukadam S; Chandrasekharan A; Das S; Vallathol D; D'Souza H; Kumar A; Agrawal A; Khaddar S; Rathnasamy N; Shenoy R; Kashyap L; Rai RK; Abraham G; Saha S; Majumdar S; Karuvandan N; Simha V; Babu V; Elamarthi P; Rajpurohit A; Kumar KAP; Srikanth A; Ravind R; Banavali S; Prabhash K
Lancet Glob Health; 2020 Sep; 8(9):e1213-e1222. PubMed ID: 32827483
[TBL] [Abstract][Full Text] [Related]
14. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
[TBL] [Abstract][Full Text] [Related]
15. Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.
Thwaites GE; Scarborough M; Szubert A; Nsutebu E; Tilley R; Greig J; Wyllie SA; Wilson P; Auckland C; Cairns J; Ward D; Lal P; Guleri A; Jenkins N; Sutton J; Wiselka M; Armando GR; Graham C; Chadwick PR; Barlow G; Gordon NC; Young B; Meisner S; McWhinney P; Price DA; Harvey D; Nayar D; Jeyaratnam D; Planche T; Minton J; Hudson F; Hopkins S; Williams J; Török ME; Llewelyn MJ; Edgeworth JD; Walker AS;
Lancet; 2018 Feb; 391(10121):668-678. PubMed ID: 29249276
[TBL] [Abstract][Full Text] [Related]
16. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
Nyang'wa BT; Berry C; Kazounis E; Motta I; Parpieva N; Tigay Z; Moodliar R; Dodd M; Solodovnikova V; Liverko I; Rajaram S; Rassool M; McHugh T; Spigelman M; Moore DA; Ritmeijer K; du Cros P; Fielding K;
Lancet Respir Med; 2024 Feb; 12(2):117-128. PubMed ID: 37980911
[TBL] [Abstract][Full Text] [Related]
17. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
18. Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia: the ARREST RCT.
Thwaites GE; Scarborough M; Szubert A; Saramago Goncalves P; Soares M; Bostock J; Nsutebu E; Tilley R; Cunningham R; Greig J; Wyllie SA; Wilson P; Auckland C; Cairns J; Ward D; Lal P; Guleri A; Jenkins N; Sutton J; Wiselka M; Armando GR; Graham C; Chadwick PR; Barlow G; Gordon NC; Young B; Meisner S; McWhinney P; Price DA; Harvey D; Nayar D; Jeyaratnam D; Planche T; Minton J; Hudson F; Hopkins S; Williams J; Török ME; Llewelyn MJ; Edgeworth JD; Walker AS
Health Technol Assess; 2018 Oct; 22(59):1-148. PubMed ID: 30382016
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
[TBL] [Abstract][Full Text] [Related]
20. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Borchmann P; Plütschow A; Kobe C; Greil R; Meissner J; Topp MS; Ostermann H; Dierlamm J; Mohm J; Thiemer J; Sökler M; Kerkhoff A; Ahlborn M; Halbsguth TV; Martin S; Keller U; Balabanov S; Pabst T; Vogelhuber M; Hüttmann A; Wilhelm M; Zijlstra JM; Moccia A; Kuhnert G; Bröckelmann PJ; von Tresckow B; Fuchs M; Klimm B; Rosenwald A; Eich H; Baues C; Marnitz S; Hallek M; Diehl V; Dietlein M; Engert A
Lancet Oncol; 2021 Feb; 22(2):223-234. PubMed ID: 33539742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
